An 11-year-old aspiring dancer has been diagnosed with a skin condition that makes her allergic to her own tears and sweat, making it excruciatingly painful for her to continue dancing. Hospitalized with severe eczema, she is now trialling a new injection treatment called Dupixent, but still experiences painful facial flares. Australian children have one of the highest incidences of eczema in the world, and the extreme heat is exacerbating the issue. There is currently no cure for eczema, so managing symptoms is crucial, with tips including avoiding harsh skincare products and identifying potential allergens.
The inflammation-targeting therapy Dupixent, developed by Sanofi and Regeneron Pharmaceuticals, has shown success in a Phase 3 trial for patients with chronic lung disease COPD. If approved, it would be the first biologic treatment for COPD, potentially expanding the market for the blockbuster medicine.
Sanofi and Regeneron's anti-inflammatory drug Dupixent showed a 30% reduction in acute exacerbations of chronic obstructive pulmonary disease (COPD) in a one-year clinical trial. The benefits of the drug were seen within two weeks and sustained throughout the trial. Sanofi is discussing with regulators whether the results are substantial enough to support a regulatory review or whether another ongoing trial is required. Dupixent is approved to treat conditions including asthma and eczema and is expected to generate up to €13bn ($14.2bn) in sales in its best year.
Sanofi and Regeneron's jointly developed asthma drug Dupixent has shown promise in treating COPD patients, according to new data from a phase three clinical trial. The drug reduced bad bouts of chronic obstructive pulmonary disease by 30% compared with a placebo over 52 weeks. Dupixent is already approved for asthma and some skin conditions, but it could become the first new treatment in over a decade for COPD. The trial enrolled COPD patients with type 2 inflammation, and those who received Dupixent showed improvements in lung function, quality of life, and respiratory symptoms. A second phase three trial of Dupixent in COPD is ongoing, with data expected in 2024.
Sanofi's asthma drug Dupixent, developed with Regeneron, has met all targets in a late-stage clinical trial to treat "smoker's lung" or chronic obstructive pulmonary disease (COPD), potentially adding billions to the French drugmaker's growth prospects. The drug led to a 30% reduction in moderate or severe acute exacerbations of COPD, and also showed improvements in lung function, quality of life, and respiratory symptoms. Analysts predict that the market consensus for 2027 Dupixent sales of 15.7 billion euros would likely be topped-up by between 1 and 2 billion euros.
